Publications by authors named "Changbin Xie"
Programmed death ligand 1 (PD-L1), an important immune checkpoint molecule, is abnormally activated in non-small cell lung cancer (NSCLC), which can interact with programmed death 1 to aid cancer cells in evading immune surveillance. Furthermore, tumor driver genes may be involved in the occurrence and development of NSCLC and have a potential role in PD-L1-mediated immune escape mechanisms. Therefore, the present study aimed to assess the behavioral and regulatory mechanisms by which circular RNA ENTPD7 (circENTPD7; hsa_circ_0019421) induces an immune response in the progression of NSCLC cells.
View Article and Find Full Text PDFArticle Synopsis
- Researchers investigated the expression of FAP-derived CXCL1 in nasopharyngeal carcinoma (NPC) to identify its potential as a biomarker for predicting distant metastasis and its relationship with PD-L1 expression.
- The study involved 345 patients and revealed a CXCL1_FAP phenotype in cancer-associated fibroblasts (CAFs) that effectively categorized patients into low and high-risk groups for metastasis based on their survival outcomes.
- The findings suggest that the CXCL1_FAP phenotype serves as an independent prognostic factor and may enhance the effectiveness of anti-PD-1/PD-L1 immunotherapy in advanced NPC.
Background And Purpose: Whether concurrent chemoradiotherapy (CCRT) benefits the older (age ≥ 60 years) patients with stage II nasopharyngeal carcinoma (NPC) has not been determined. This study aimed to compare the outcomes and toxicities of CCRT with Intensity-Modulated Radiotherapy (IMRT) alone in older patients with stage II NPC.
Materials And Methods: Between January 2010 and December 2017, 220 older (age ≥ 60 years) patients with stage II NPC were analyzed.